These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35963791)

  • 21. The Cardiologist and the Cancer Patient: Challenges to Cardio-Oncology (or Onco-Cardiology) and Call to Action.
    Okwuosa TM; Prabhu N; Patel H; Kuzel T; Venugopal P; Williams KA; Paner A
    J Am Coll Cardiol; 2018 Jul; 72(2):228-232. PubMed ID: 29976296
    [No Abstract]   [Full Text] [Related]  

  • 22. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
    Alsina M; Trudel S; Furman RR; Rosen PJ; O'Connor OA; Comenzo RL; Wong A; Kunkel LA; Molineaux CJ; Goy A
    Clin Cancer Res; 2012 Sep; 18(17):4830-40. PubMed ID: 22761464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cardiology units and organizational models of heart transplantation centers in Italy: a survey by the Italian Association of Hospital Cardiologists-Italian Society of Organ Transplantation (ANMCO-SITO)].
    Palmieri V; Piccioni LL; Amarelli C; Gentili G; Chinaglia A; Fiscella D; Deales A; Lopriore V; Iacoviello M; Di Eusanio M; Lucà F; Colivicchi F; Boggi U; Gabrielli D
    G Ital Cardiol (Rome); 2021 Mar; 22(3):239-243. PubMed ID: 33687377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.
    Stewart AK
    Future Oncol; 2015; 11(15):2121-36. PubMed ID: 26125319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Proteasome inhibitors in treatment of multiple myeloma].
    Kubiczková L; Matějíková J; Sedlaříková L; Kryukov F; Hájek R; Sevčíková S
    Klin Onkol; 2013; 26(1):11-8. PubMed ID: 23528167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
    Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
    Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.
    Herndon TM; Deisseroth A; Kaminskas E; Kane RC; Koti KM; Rothmann MD; Habtemariam B; Bullock J; Bray JD; Hawes J; Palmby TR; Jee J; Adams W; Mahayni H; Brown J; Dorantes A; Sridhara R; Farrell AT; Pazdur R
    Clin Cancer Res; 2013 Sep; 19(17):4559-63. PubMed ID: 23775332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteasome Inhibitors as a Potential Cause of Heart Failure.
    Koulaouzidis G; Lyon AR
    Heart Fail Clin; 2017 Apr; 13(2):289-295. PubMed ID: 28279415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
    Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
    Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel agents in the treatment of multiple myeloma: a review about the future.
    Naymagon L; Abdul-Hay M
    J Hematol Oncol; 2016 Jun; 9(1):52. PubMed ID: 27363832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis.
    Dinner S; Witteles W; Witteles R; Lam A; Arai S; Lafayette R; George TI; Schrier SL; Liedtke M
    Br J Haematol; 2013 May; 161(3):367-72. PubMed ID: 23432783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Amyloidosis associated with multiple myeloma].
    Hirota K; Furusawa S
    Ryoikibetsu Shokogun Shirizu; 1998; (22 Pt 3):480-3. PubMed ID: 9851195
    [No Abstract]   [Full Text] [Related]  

  • 34. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
    Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
    Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myeloma: diagnosis complications and supportive care.
    Morgan G
    Hematology; 2012 Apr; 17 Suppl 1():S109-11. PubMed ID: 22507795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors.
    Alkharabsheh O; Sidiqi MH; Aljama MA; Gertz MA; Frankel AE
    Acta Haematol; 2020; 143(2):118-123. PubMed ID: 31311009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple myeloma: current concepts in diagnosis and management.
    Paredes JM; Mitchell BS
    Med Clin North Am; 1980 Jul; 64(4):729-42. PubMed ID: 6995732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe amyloidosis with mild multiple myeloma--an unusual course.
    Zeidman A; Sender BZ; Yarmolovsky A; Fradin Z; Mittelman M
    Haematologia (Budap); 2000; 30(1):55-9. PubMed ID: 10841327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preventive cardiology: what the interventional cardiologist needs to know in 2019.
    McEvoy JW; Mylotte D
    EuroIntervention; 2019 Aug; 15(5):389-391. PubMed ID: 31456568
    [No Abstract]   [Full Text] [Related]  

  • 40. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.
    Trudel S; Lendvai N; Popat R; Voorhees PM; Reeves B; Libby EN; Richardson PG; Anderson LD; Sutherland HJ; Yong K; Hoos A; Gorczyca MM; Lahiri S; He Z; Austin DJ; Opalinska JB; Cohen AD
    Lancet Oncol; 2018 Dec; 19(12):1641-1653. PubMed ID: 30442502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.